These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37209611)

  • 21. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China.
    Fang MT; Su YF; An HR; Zhang PZ; Deng GF; Liu HM; Mao Z; Zeng JF; Li G; Yang QT; Wang ZY
    BMC Infect Dis; 2021 Sep; 21(1):1015. PubMed ID: 34583653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India.
    Shewade HD; Kokane AM; Singh AR; Verma M; Parmar M; Chauhan A; Chahar SS; Tiwari M; Khan SN; Gupta V; Tripathy JP; Nagar M; Singh SK; Mehra PK; Kumar AM
    BMC Health Serv Res; 2017 Apr; 17(1):249. PubMed ID: 28376789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
    Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
    Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study.
    Yu Q; Luo H; Hu S; Sun D; Nie Q; Yan J
    Front Cell Infect Microbiol; 2023; 13():1118424. PubMed ID: 37197206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
    Ngabonziza JS; Habimana YM; Decroo T; Migambi P; Dushime A; Mazarati JB; Rigouts L; Affolabi D; Ivan E; Meehan CJ; Van Deun A; Fissette K; Habiyambere I; Nyaruhirira AU; Turate I; Semahore JM; Ndjeka N; Muvunyi CM; Condo JU; Gasana M; Hasker E; Torrea G; de Jong BC
    Int J Tuberc Lung Dis; 2020 Mar; 24(3):329-339. PubMed ID: 32228764
    [No Abstract]   [Full Text] [Related]  

  • 27. Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study.
    Jiang W; Peng Y; Wang X; Elbers C; Tang S; Huang F; Chen B; Cobelens F
    BMJ Open; 2021 Apr; 11(4):e047023. PubMed ID: 33846156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings.
    Liu Z; Dong H; Wu B; Zhang M; Zhu Y; Pang Y; Wang X
    J Infect; 2019 Oct; 79(4):349-356. PubMed ID: 31400354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nationwide Treatment Outcomes of Patients With Multidrug/Rifampin-Resistant Tuberculosis in Korea, 2011-2017: A Retrospective Cohort Study (Korean TB-POST).
    Choi H; Mok J; Kang YA; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
    J Korean Med Sci; 2023 Feb; 38(5):e33. PubMed ID: 36747362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcomes of retreated patients with isoniazid/rifampicin resistant pulmonary tuberculosis.
    Zhang L; Han X; Ge Q; Shu W; Sun Y; Gao J; Xie S; Wang J; Gao W
    BMC Infect Dis; 2024 Jan; 24(1):7. PubMed ID: 38166793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of treatment outcomes of multidrug-resistant tuberculosis under programmatic conditions and factors influencing the outcomes in Hyderabad District.
    Kandi S; K TK; Kandi SR; Mathur N; D CD; Adepu R
    Indian J Tuberc; 2021 Jul; 68(3):379-383. PubMed ID: 34099204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study on the direct economic burden and relevant influencing factors of 233 multidrug/rifampicin-resistant pulmonary tuberculosis patients in Jiangsu Province].
    Ding H; Lu P; Ding XY; Li ZQ; Zhu LM; Liu Q
    Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Sep; 45(9):1251-1257. PubMed ID: 39307699
    [No Abstract]   [Full Text] [Related]  

  • 37. Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children
    McQuaid CF; Cohen T; Dean AS; Houben RMGJ; Knight GM; Zignol M; White RG
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32855219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in drug-resistant tuberculosis after the implementation of the DOTS strategy in Shenzhen, China, 2000-2013.
    Zhu L; Yang YZ; Guan HY; Cheng SM; Jin YY; Tan WG; Wu QF; Liu XL; Zhao MG; Lu ZH; Jia ZW
    Int J Tuberc Lung Dis; 2017 Jul; 21(7):759-765. PubMed ID: 28633700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.